Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-17 of 17 (Search time: 0.004 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2011
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Cortes, J.
;
Hochhaus, A.
;
Hughes, T.
;
Kantarjian, H.
2011
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Kantarjian, H.
;
Giles, F.
;
Bhalla, K.
;
Pinilla-Ibarz, J.
;
Larson, R.
;
Gattermann, N.
;
Ottmann, O.
;
Hochhaus, A.
;
Radich, J.
;
Saglio, G.
;
Hughes, T.
;
Martinelli, G.
;
Kim, D.
;
Shou, Y.
;
Gallagher, N.
;
Blakesley, R.
;
Baccarani, M.
;
Cortes, J.
;
le Coutre, P.
2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Tang, M.
;
Gonen, M.
;
Quintas-Cardama, A.
;
Cortes, J.
;
Kantarjian, H.
;
Field, C.
;
Hughes, T.
;
Branford, S.
;
Michor, F.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
Baccarani, M.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Mongay, L.
;
Mone, M.
;
Ortmann, C.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
;
Cortes, J.
;
Guilhot, F.
2012
Suboptimal responses in chronic myeloid leukemia: implications and management strategies
Jabbour, E.
;
Saglio, G.
;
Hughes, T.
;
Kantarjian, H.
2017
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
Hochhaus, A.
;
Larson, R.
;
Guilhot, F.
;
Radich, J.
;
Branford, S.
;
Hughes, T.
;
Baccarani, M.
;
Deininger, M.
;
Cervantes, F.
;
Fujihara, S.
;
Ortmann, C.
;
Menssen, H.
;
Kantarjian, H.
;
O'Brien, S.
;
Druker, B.
Discover
Author
13
Hochhaus, A.
11
Larson, R.
10
Saglio, G.
8
Kim, D.
7
Baccarani, M.
7
Guilhot, F.
6
Cortes, J.
6
Gallagher, N.
5
Rosti, G.
4
Branford, S.
.
next >
Subject
10
Benzamides
10
Piperazines
10
Pyrimidines
9
Humans
9
Imatinib Mesylate
8
Antineoplastic Agents
7
Protein Kinase Inhibitors
6
Fusion Proteins, bcr-abl
6
Leukemia, Myelogenous, Chronic, B...
6
Treatment Outcome
.
next >
Date issued
1
2017
1
2016
3
2014
2
2013
4
2012
4
2011
2
2010